Trial Profile
BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Betrixaban (Primary)
- Indications Venous thromboembolism
- Focus Therapeutic Use
- Acronyms BRAVO
- Sponsors Portola Pharmaceuticals
- 08 Jun 2020 Status changed from suspended to withdrawn prior to enrolment.
- 29 Nov 2018 Status changed from not yet recruiting to suspended.
- 20 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.